

# Liu Wensheng

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9267723/publications.pdf>

Version: 2024-02-01

24  
papers

836  
citations

623734

14  
h-index

642732

23  
g-index

24  
all docs

24  
docs citations

24  
times ranked

1135  
citing authors

#	ARTICLE	IF	CITATIONS
1	The impact of cancer-associated fibroblasts on major hallmarks of pancreatic cancer. <i>Theranostics</i> , 2018, 8, 5072-5087.	10.0	139
2	FBW7-NRA41-SCD1 axis synchronously regulates apoptosis and ferroptosis in pancreatic cancer cells. <i>Redox Biology</i> , 2021, 38, 101807.	9.0	135
3	UHRF1 promotes aerobic glycolysis and proliferation via suppression of SIRT4 in pancreatic cancer. <i>Cancer Letters</i> , 2019, 452, 226-236.	7.2	99
4	Ferroptosis: Final destination for cancer?. <i>Cell Proliferation</i> , 2020, 53, e12761.	5.3	73
5	PRMT5 enhances tumorigenicity and glycolysis in pancreatic cancer via the FBW7/cMyc axis. <i>Cell Communication and Signaling</i> , 2019, 17, 30.	6.5	72
6	TCF7L2 positively regulates aerobic glycolysis via the EGLN2/HIF-1 $\alpha$ axis and indicates prognosis in pancreatic cancer. <i>Cell Death and Disease</i> , 2018, 9, 321.	6.3	45
7	Management of solid pseudopapillary neoplasms of pancreas: A single center experience of 243 consecutive patients. <i>Pancreatology</i> , 2019, 19, 681-685.	1.1	38
8	Pin1 promotes pancreatic cancer progression and metastasis by activation of NF $\kappa$ B/IL-18 feedback loop. <i>Cell Proliferation</i> , 2020, 53, e12816.	5.3	32
9	Homeodomain-interacting protein kinase 2 suppresses proliferation and aerobic glycolysis via ERK/cMyc axis in pancreatic cancer. <i>Cell Proliferation</i> , 2019, 52, e12603.	5.3	29
10	Laparoscopic pancreaticoduodenectomy: are the best times coming?. <i>World Journal of Surgical Oncology</i> , 2019, 17, 81.	1.9	23
11	<scp>dCK</scp> negatively regulates the <scp>NRF</scp>2/<scp>ARE</scp> axis and <scp>ROS</scp> production in pancreatic cancer. <i>Cell Proliferation</i> , 2018, 51, e12456.	5.3	22
12	Oncogenic function of TRIM2 in pancreatic cancer by activating ROS-related NRF2/ITGB7/FAK axis. <i>Oncogene</i> , 2020, 39, 6572-6588.	5.9	21
13	A new facet of NDRG1 in pancreatic ductal adenocarcinoma: Suppression of glycolytic metabolism. <i>International Journal of Oncology</i> , 2017, 50, 1792-1800.	3.3	20
14	Role of hepatocyte nuclear factor 4 alpha in cell proliferation and gemcitabine resistance in pancreatic adenocarcinoma. <i>Cancer Cell International</i> , 2019, 19, 49.	4.1	19
15	SETD8 potentiates constitutive ERK1/2 activation via epigenetically silencing DUSP10 expression in pancreatic cancer. <i>Cancer Letters</i> , 2021, 499, 265-278.	7.2	16
16	MTAP Deficiency-Induced Metabolic Reprogramming Creates a Vulnerability to Cotargeting <i>De Novo</i> Purine Synthesis and Glycolysis in Pancreatic Cancer. <i>Cancer Research</i> , 2021, 81, 4964-4980.	0.9	15
17	SETD8 induces stemness and epithelial&ndash;mesenchymal transition of pancreatic cancer cells by regulating ROR1 expression. <i>Acta Biochimica Et Biophysica Sinica</i> , 2021, 53, 1614-1624.	2.0	7
18	Function and regulation of F $\beta$ box/WD repeat-containing protein 7 (Review). <i>Oncology Letters</i> , 2020, 20, 1526-1534.	1.8	7

#	ARTICLE	IF	CITATIONS
19	FGFBP1-mediated crosstalk between fibroblasts and pancreatic cancer cells via FGF22/FGFR2 promotes invasion and metastasis of pancreatic cancer. <i>Acta Biochimica Et Biophysica Sinica</i> , 2021, 53, 997-1008.	2.0	5
20	ALDOA inhibits cell cycle arrest induced by DNA damage via the ATM-PLK1 pathway in pancreatic cancer cells. <i>Cancer Cell International</i> , 2021, 21, 514.	4.1	5
21	Value of lymphadenectomy in patients with surgically resected pancreatic neuroendocrine tumors. <i>BMC Surgery</i> , 2022, 22, 160.	1.3	5
22	MBD1 promotes the malignant behavior of gallbladder cancer cells and induces chemotherapeutic resistance to gemcitabine. <i>Cancer Cell International</i> , 2019, 19, 232.	4.1	4
23	Pevonedistat Suppresses Pancreatic Cancer Growth via Inactivation of the Neddylation Pathway. <i>Frontiers in Oncology</i> , 2022, 12, 822039.	2.8	4
24	Improved tumor control with antiangiogenic therapy after treatment with gemcitabine and nabâ€paclitaxel in pancreatic cancer. <i>Clinical and Translational Medicine</i> , 2021, 11, e398.	4.0	1